
Tevogen Bio Holdings Inc.
97
Recent developments highlight Tevogen Bio's strategic acquisition efforts, AI technology progress, and shareholder initiatives.
- Tevogen advanced strategic acquisition plans with potential to add $100 million in annual revenue [N3].
- The company signed a letter of intent to evaluate an MSO acquisition, which was positively received by the market [N4].
- Tevogen.AI's PredicTcell model is nearing completion as the company begins commercial readiness work [N5].
- The board is evaluating a potential one-time special cash dividend to shareholders [N6].
- Tevogen aligned its long-term stock-based incentive program with company milestones, including revenue targets [N7].
Tevogen Bio Holdings Inc. operates in the biotechnology sector with a focus on immunotherapy and AI-driven drug discovery technologies. The company is led by experienced executives including CEO Dr. Ryan Saadi and Chief Scientific Officer Dr. Neal Flomenberg. It maintains a governance structure with an independent board and audit committee. The company has recently undertaken a reverse stock split and has ongoing initiatives to expand its product pipeline and commercial capabilities through AI technology and strategic acquisitions.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Tevogen Bio Holdings Inc. is a biotechnology company with detailed disclosures on governance, executive leadership, and financials. The company reported a net loss of $7.0 million and a current ratio of 0.13 as of September 30, 2026. Recent news highlights include strategic acquisition plans with potential to add $100 million in annual revenue, progress on AI-driven PredicTcell model commercial readiness, and board considerations for a special cash dividend [S1][S2][N3][N4][N5][N6].
The company’s advancement of AI-driven immunotherapy platforms and near completion of the PredicTcell model indicate progress toward commercial readiness. Strategic acquisition plans with potential to add significant annual revenue demonstrate active growth initiatives. Alignment of long-term stock-based incentives with company milestones may support management focus on execution. Board consideration of a special cash dividend reflects potential shareholder value initiatives [N3][N5][N6][N7].
Tevogen Bio reported a net loss of $7.0 million and has a low current ratio of 0.13 as of September 30, 2026, indicating liquidity constraints. The company has zero cash and equivalents reported, which may pose operational risks. The biotechnology sector’s inherent risks include regulatory approvals, clinical trial outcomes, and competitive pressures. The company’s reliance on strategic acquisitions introduces integration and execution risks. The reverse stock split may reflect past stock price challenges [S2].
Tevogen Bio’s moat is supported by its integration of advanced AI technologies, such as the PredicTcell model, into immunotherapy development, which aims to accelerate clinical trial participation and enhance pipeline development. The company’s leadership team has extensive experience in healthcare and biopharmaceutical markets, and it is actively pursuing strategic acquisitions to expand its revenue base. Its proprietary AI-driven immunologically active peptide prediction technology, as evidenced by international patent applications, contributes to its competitive positioning.
• Liquidity Risk: The company reported zero cash and equivalents and a current ratio of 0.13 as of September 30, 2026, indicating limited short-term liquidity to meet obligations.
• Operational and Execution Risk: Execution of strategic acquisitions and integration of AI-driven technologies require effective management and operational capabilities.
• Clinical and Regulatory Risk: As a biotechnology company, Tevogen Bio faces risks related to clinical trial outcomes, regulatory approvals, and market acceptance of its therapies.
• Market and Competitive Risk: The biotechnology sector is highly competitive with rapid technological changes, which may impact the company’s market position and growth.
Business trends: The company is advancing AI-driven immunotherapy technologies and pursuing strategic acquisitions to expand revenue.
Execution milestones: Near completion of the PredicTcell model and evaluation of MSO acquisition demonstrate progress.
Key risks: Liquidity constraints, operational execution challenges, clinical and regulatory uncertainties, and competitive pressures.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Tevogen Bio Holdings Inc. is a biotechnology company incorporated in Delaware with its principal executive offices in Warren, New Jersey.
- The company’s common stock and warrants are listed on The Nasdaq Stock Market under the symbols TVGN and TVGNW respectively.
- Tevogen Bio’s board consists of six directors divided into three classes with staggered three-year terms.
- Key executives include Dr. Ryan Saadi as CEO and Chairperson, Kirti Desai as CFO, and Dr. Neal Flomenberg as Chief Scientific Officer and Global R&D Lead.
- The company completed a 1-for-50 reverse stock split on March 6, 2026.
- As of April 28, 2026, the company had 4,187,505 shares of common stock outstanding.
- The company’s aggregate market value of common stock held by non-affiliates was approximately $63.7 million as of June 30, 2025.
- Tevogen Bio has an Audit Committee composed of independent directors, including an Audit Committee financial expert.
- The company has adopted a code of business conduct and ethics applicable to all directors, officers, and employees.
- Financial snapshot as of September 30, 2026, shows cash and equivalents of $0, current assets of $841,136, current liabilities of $6,371,539, resulting in a current ratio of 0.13 and a cash ratio of 0.
- Net income for the nine months ended September 30, 2026, was a loss of $7,003,801, with basic and diluted EPS of -$1.76 per share.
- The company is advancing strategic acquisition plans with potential to add $100 million in annual revenue and has signed a letter of intent to evaluate an MSO acquisition [N3][N4].
- Tevogen.AI's PredicTcell model is nearing completion as the company begins commercial readiness work [N5].
- The board is evaluating a potential one-time special cash dividend to shareholders [N6].
- Tevogen is aligning its long-term stock-based incentive program with company milestones including revenue [N7].
- The company has received buy recommendations from analysts such as D. Boral Capital [N8].
Generated 2026-11-17
- S1 | 2026-04-30 | 10-K/A
- S2 | 2026-11-16 | 10-Q
- N1 | 2026-07-28 | www.nasdaq.com | Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired | https://www.nasdaq.com/articles/top-biotech-gainers-goss-file-seralutinib-nda-sep-omer-gains-azns-loss-fbrx-acquired
- N2 | 2026-05-29 | www.nasdaq.com | Top Biotech Gainers: SPRC Deal Gets Nod, CODX Rallies, OTLK, AKTX, FTRE Drawing Investor Interest | https://www.nasdaq.com/articles/top-biotech-gainers-sprc-deal-gets-nod-codx-rallies-otlk-aktx-ftre-drawing-investor
- N3 | 2026-05-29 | www.nasdaq.com | Tevogen Advances Strategic Acquisition Plans With Potential To Add $100 Million In Annual Revenue | https://www.nasdaq.com/articles/tevogen-advances-strategic-acquisition-plans-potential-add-100-million-annual-revenue
- N4 | 2026-05-21 | www.nasdaq.com | Tevogen Signs LOI To Evaluate MSO Acquisition; Stock Up | https://www.nasdaq.com/articles/tevogen-signs-loi-evaluate-mso-acquisition-stock
- N5 | 2026-04-28 | www.nasdaq.com | Tevogen.AI's PredicTcell Model Nears Completion As Company Begins Commercial Readiness Work | https://www.nasdaq.com/articles/tevogenais-predictcell-model-nears-completion-company-begins-commercial-readiness-work
- N6 | 2026-01-30 | www.globenewswire.com | Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders | https://www.globenewswire.com/news-release/2026/01/30/3229749/0/en/Tevogen-Board-to-Evaluate-Potential-One-Time-Special-Cash-Dividend-to-Shareholders.html
- N7 | 2026-01-29 | www.globenewswire.com | Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue | https://www.globenewswire.com/news-release/2026/01/29/3229032/0/en/Tevogen-to-Align-Long-Term-Stock-Based-Incentive-Program-With-Company-Milestones-Including-Revenue.html
- N8 | 2025-11-21 | www.nasdaq.com | D. Boral Capital Maintains Tevogen Bio Holdings (TVGN) Buy Recommendation | https://www.nasdaq.com/articles/d-boral-capital-maintains-tevogen-bio-holdings-tvgn-buy-recommendation
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


